Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combination of Yiqi Jianpi Yangxue Decoction and chemotherapy on quality of life and adverse reactions of patients with recurrent ovarian cancer

Qingling Zhang¹, Wenjuan Zhang², Xiao Wang³, Xueling Chen², Yewu Gao⁴

¹Department of Traditional Chinese Medicine; ²Department of Obstetrics, The Second Children and Women's Healthcare of Jinan City, Jinan 271100; ³Department of Respiration, Tai'an Cancer Prevention and Treatment Hospital, Taian 271000; ⁴Department of Gynecology, Zhangqiu District People's Hospital, Jinan 250200, Shandong Province, China.

For correspondence:- Yewu Gao Email: baohejiv@163.com

Accepted: 29 September 2021 Published: 31 October 2021

Citation: Zhang Q, Zhang W, Wang X, Chen X, Gao Y. Effect of combination of Yiqi Jianpi Yangxue Decoction and chemotherapy on quality of life and adverse reactions of patients with recurrent ovarian cancer. Trop J Pharm Res 2021; 20(10):2227-2233 doi: 10.4314/tjpr.v20i10.30

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of combined treatment with Yiqi Jianpi Yangxue Decoction and chemotherapy (carboplatin + paclitaxel) on quality of life (QOL) and adverse reactions of patients with recurrent ovarian cancer (ROC).

Methods: One hundred and fourteen (114) ROC patients in The Second Children & Women’s Healthcare of Jinan City were split into chemotherapy group (n = 60) and combination group (n = 54), based on whether or not they were treated with Yiqi Jianpi Yangxue Decoction. Differences in clinical efficacy, adverse reactions, levels of tumor marker, levels of immune indexes, and scores on Karnofsky Performance Status (KPS) between the two groups were evaluated.

Results: Treatment effectiveness was higher in the combination group than in the chemotherapy group (p < 0.05). Compared with the chemotherapy group, post-treatment levels of HE4 and CA125 in the combination group were lower, while the levels of CD₃⁺, CD₄⁺ and CD₈⁺, and population of NK cells were higher (p < 0.05). After treatment, the KPS score in the combination group was higher than the corresponding score in the chemotherapy group (p < 0.05).

Conclusion: Combination of Yiqi Jianpi Yangxue Decoction and chemotherapy (carboplatin + paclitaxel) produces significant enhancement of clinical efficacy in the treatment of ROC. The combination treatment is highly safe, and improves the health status and QOL of patients. Therefore, the combination treatment appears to be suitable for the management of ovarian cancer.

Keywords: Recurrent ovarian cancer, Yiqi Jianpi Yangxue Decoction, Chemotherapy, Carboplatin, Paclitaxel, Adverse reactions, Quality of life